Últimas noticias sobre Elastic (NYSE:ESTC) Bolsa

Elastic

Elastic is a software company based in Mountain View, California, focusing on search-adjacent products. Its search engine allows it to process both structured and unstructured data while gleaning insights from that data. The firm's primary focus is on enterprise search, observability, and security.

Elastic NV

Goldman Sachs analyst Paul Choi maintains Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Buy and lowers the price target from $60 to $52.

News

Price Target

Analyst Ratings

XENE

Goldman Sachs Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $52

<a href="https://www.youtube.com/watch?v=LepQacb-5Sg" title="https://www.youtube.com/watch?v=LepQacb-5Sg">https://www.youtube.com/watch?v=LepQacb-5Sg</a>

Macro Economic Events

Politics

Global

Economics

General

President Trump Says We Will Be Hearing From Russia Very Shortly; Minerals Deal To Be Signed Next Thursday

UBS analyst Vilas Abraham maintains Capital Southwest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSWC#NASDAQ">CSWC</a>) with a Neutral and lowers the price target from $23.5 to $20.5.

CSWC

UBS Maintains Neutral on Capital Southwest, Lowers Price Target to $20.5

Goldman Sachs analyst Adam Hotchkiss maintains Workiva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WK#NYSE">WK</a>) with a Buy and lowers the price target from $118 to $105.

Goldman Sachs Maintains Buy on Workiva, Lowers Price Target to $105

Federal Reserve

President Trump Says Federal Reserve Chair Powell Will Leave If I Ask Him To; I'm Not Happy With Him

Goldman Sachs analyst Paul Choi maintains Vir Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIR#NASDAQ">VIR</a>) with a Buy and lowers the price target from $28 to $21.

Goldman Sachs Maintains Buy on Vir Biotechnology, Lowers Price Target to $21

WIIM

Avis Budget Group shares are trading higher. The stock may be up in sympathy with competitor Hertz, which rose after Pershing Square disclosed a stake.

Goldman Sachs analyst Paul Choi maintains UroGen Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URGN#NASDAQ">URGN</a>) with a Neutral and lowers the price target from $22 to $16.

URGN

Goldman Sachs Maintains Neutral on UroGen Pharma, Lowers Price Target to $16

New York, New York, April 17, 2025 (GLOBE NEWSWIRE) -- AI Transportation Acquisition Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AITR#NASDAQ">AITR</a>), a publicly-listed special purpose acquisition company ("AITR"), today announced that The Nasdaq Stock Market, LLC ("Nasdaq") determined to suspend trading and delist AITR's securities from Nasdaq due to AITR's failure to pay certain fees required by Listing Rule 5250(f), unless AITR appeals this determination. AITR does not intend to request a hearing to appeal the determination, which decision was based on a careful review of numerous factors, including the potential for limiting the significant costs associated with remaining listed on Nasdaq and complying with Nasdaq listing standards.
AITR's securities includes its ordinary shares value $0.0001 per share (the "Ordinary Shares"), its publicly-traded rights whereby each right provides the holder with a right to acquire 1/8th of one Ordinary Share (the "Rights"), and AITR's publicly-traded units, consisting of one Ordinary Share and one Right.
Nasdaq is expected to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission relating to the delisting of AITR's securities. Suspension of trading of AITR's securities occurred at the opening of business on April 16, 2025. The removal of AITR's securities from Nasdaq will be effective 10 days after the filing of the Form 25.
Following the delisting, AITR expects that the Ordinary Shares will be traded on a market operated by the OTC Markets Group Inc. (the "OTC"). No assurances can be provided, however, that trading of the Ordinary Shares on the OTC will occur.
On April 11, 2025, AITR received a notice (the "Notice") from Nasdaq stating that AITR's failure to file its Annual Report on Form 10-K for the year ended December 31, 2021 also serves a basis for delisting AITR's securities from Nasdaq.

AITR

AI Transportation Acquisition Announces Delisting From Nasdaq And Expected Securities Deregistration

Goldman Sachs maintains Trinity Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRN#NYSE">TRN</a>) with a Neutral and lowers the price target from $36 to $31.

Goldman Sachs Maintains Neutral on Trinity Indus, Lowers Price Target to $31

UBS analyst Peter Grom maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Neutral and lowers the price target from $176 to $154.

UBS Maintains Neutral on Clorox, Lowers Price Target to $154

<a href="https://www.youtube.com/watch?v=LepQacb-5Sg">https://www.youtube.com/watch?v=LepQacb-5Sg</a>
&nbsp;

President Trump Says He And Italy's Meloni Talked About Trade; Italy's Meloni Says Italy Will Have To Increase LNG Imports, Want To Work Together On Nuclear

Stargate is considering a <a target="_blank" href="https://www.benzinga.com/topic/stargate" rel="noreferrer noopener">future investment in</a> the U.K. to build the global infrastructure needed to support advanced artificial intelligence models.
Sir Keir Starmer&#8217;s government recently announced plans to boost investment in its growing AI industry, including developers&#8217; access to energy, the Financial Times <a target="_blank" href="https://www.ft.com/content/435f0142-8bc1-43dd-9648-d7f05de1dee6" rel="noreferrer noopener">reported</a>, citing unnamed sources familiar with the matter.
The OpenAI and SoftBank (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBF#OTC">SFTBF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBY#OTC">SFTBY</a>)- backed AI infrastructure joint venture is raising $100 billion to invest in AI infrastructure projects.
Also Read: <a target="_blank" href="https://www.benzinga.com/media/25/03/44327422/softbank-to-build-676-million-ai-data-center-in-japan-linked-to-openai-partnership" rel="noreferrer noopener">SoftBank To Build $676 Million AI Data Center In Japan, Linked To OpenAI Partnership</a>
The figure could reach $500 billion over the next four years. Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) will supply 64,000 AI chips for the <a target="_blank" href="https://www.benzinga.com/25/03/44188361/nvidia-powers-openai-and-oracles-100-billion-stargate-first-ai-data-center-set-to-launch-in-texas" rel="noreferrer noopener">Stargate data center</a> in Texas. OpenAI tapped Oracle Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) to supervise the supercomputer being built in the Abilene data center.
Investment in the U.K. has been considered part of a future international expansion despite the focus on the U.S.
U.K.&#8217;s plans to boost data centers&#8217; access to electricity have stimulated the project&#8217;s interest, the Financial Times reported, citing unnamed sources familiar with the matter.&nbsp;
OpenAI said the U.K. was one of its key overseas markets.
Lately, OpenAI has been lobbying European governments to relax regulations and invest in data center infrastructure.
Last Wednesday, the European Commission announced its plan to invest more in AI data centers, including regulatory relaxations.
However, the project&#8217;s ambition remains vulnerable to President Donald Trump&#8217;s new tariff policies.
Trump&#8217;s 145% tariff on China alone could translate into over $11 billion surge in annual costs for U.S. data centre developers, Financial Times cited Altana.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43139410/softbanks-role-in-500-billion-stargate-ai-venture-seen-as-major-growth-driver-analyst-says" target="_blank" rel="noreferrer noopener">SoftBank&#8217;s Role in $500 Billion Stargate AI Venture Seen as Major Growth Driver, Analyst Says</a></li>
</ul>
Photo by AKOBCHUK via Shuttesrtock

Tech

Media

NVDA

ORCL

SFTBF

SFTBY

OpenAI And SoftBank's Stargate Considers Major UK Investment To Fuel AI Growth

Goldman Sachs analyst Chris Merwin maintains Sprout Social (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPT#NASDAQ">SPT</a>) with a Neutral and lowers the price target from $29 to $23.

Goldman Sachs Maintains Neutral on Sprout Social, Lowers Price Target to $23

Goldman Sachs analyst Adam Hotchkiss maintains Similarweb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMWB#NYSE">SMWB</a>) with a Buy and lowers the price target from $13 to $10.

SMWB

Goldman Sachs Maintains Buy on Similarweb, Lowers Price Target to $10

UBS analyst Doug Harter maintains Ares Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCC#NASDAQ">ARCC</a>) with a Neutral and lowers the price target from $22 to $21.

ARCC

UBS Maintains Neutral on Ares Capital, Lowers Price Target to $21

Goldman Sachs analyst Paul Choi maintains Regenxbio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>) with a Neutral and lowers the price target from $14 to $12.

RGNX

Goldman Sachs Maintains Neutral on Regenxbio, Lowers Price Target to $12

Trump Media & Technology Group shares are trading higher Thursday after the company sent a complaint to federal regulators, citing potential market manipulation involving its stock.

Goldman Sachs analyst Paul Choi maintains Phathom Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAT#NASDAQ">PHAT</a>) with a Neutral and lowers the price target from $12 to $10.

PHAT

Goldman Sachs Maintains Neutral on Phathom Pharmaceuticals, Lowers Price Target to $10

Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) may be setting up for a breakout moment, with Felix Jauvin dubbing it the &#8220;<a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44869153/unrealized-bitcoin-losses-hit-all-time-high-glassnode-says-bear-market-signs">cleanest trade after the trade</a>."
What Happened: In an <a href="https://x.com/fejau_inc/status/1912576594083971147">article</a> on April 17 on X, &#8216;Forward Guidance&#8217; podcast host Jauvin said that he sees investors reducing risk and offloading positions. 
Jauvin argues that Bitcoin is positioned to benefit from a global capital rotation unlike anything seen before in its history since it has been driven by three key factors: 
<ul>
<li>Investor appetite for high-beta risk assets</li>
<li>Its correlation with gold</li>
<li>Global liquidity </li>
</ul>
With the dollar weakening, U.S. equities underperforming global peers and gold hitting all-time highs, signs are building for a shift away from domestic markets and into borderless assets like Bitcoin.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44869153/unrealized-bitcoin-losses-hit-all-time-high-glassnode-says-bear-market-signs">Unrealized Bitcoin Losses Hit All-Time High, Glassnode Says: Bear Market Signs?</a>
Why It Matters: Jauvin sees Bitcoin as uniquely positioned offering global liquidity exposure without geopolitical baggage. 
Unlike U.S. tech stocks or foreign equities vulnerable to tariffs, political risk, or trade wars, Bitcoin is non-sovereign and censorship resistant.
While the current environment is marked by deleveraging and volatility, the &#8220;trade after the trade&#8221; is Bitcoin. 
Gold's current strength validates the shift in regime, and Bitcoin is likely to follow once the overhang of &#8220;degrossing&#8221; clears.
For a risk-seeking macro trader, Bitcoin offers asymmetric upside as a high-beta global liquidity asset that doesn't rely on the fortunes of any one country.
"You can't tariff Bitcoin," he notes, framing it as a macro hedge and clean play on global liquidity, especially as the rest of the world leans into fiscal expansion.
In this evolving macro environment, Fejau believes Bitcoin could finally decouple from U.S. equities and resume its trajectory as the "fastest horse"—a term famously used by Paul Tudor Jones to describe BTC's potential in past cycles. 
"This market regime is what Bitcoin was built for," he concludes.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44863580/bitcoin-stuck-below-85000-bull-run-shakeout-or-bearish-downtrend">Bitcoin Stuck Below $85,000: Bull Run Shakeout Or Bearish Downtrend?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin Is the 'Cleanest Trade' Since 'You Can't Tariff Bitcoin,' Expert Says

Press Releases

Elastic N.V. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - ESTC

Elastic N.V. (ESTC) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Legal

Elastic N.V. Investors: Please contact the Portnoy Law Firm to recover your losses. April 14, 2025 Deadline to file Lead Plaintiff Motion.

ESTC Deadline: ESTC Purchasers with Losses in Excess of $100K Have Opportunity to Lead Elastic N.V. Securities Fraud Lawsuit

ESTC DEADLINE NOTICE: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Elastic N.V. Investors to Secure Counsel Before Important April 14 Deadline in Securities Class Action – ESTC

Comments

Elastic

Noticias

Últimas noticias sobre Elastic (NYSE:ESTC) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL